Intervention not reported
Viral clearance at 14 days · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities
It is very uncertain whether the intervention changes viral clearance at 14 days (very low certainty).
1 finding from 1 review
Treatment failure (annual failure rate) · Children with moderately deep dentine caries in primary molars, no pulp therapy
Etch-and-rinse adhesion failed more than self-etch (19.5% vs 7.0% annual failure) in one RCT; low quality of evidence (ungraded).
1 finding from 1 review
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus may leads to higher clinical remission compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in clinical improvement compared with beclometasone (low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in serious adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus may leads to higher clinical improvement compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes clinical remission compared with ciclosporin (very low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes clinical improvement compared with ciclosporin (very low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in clinical remission compared with beclometasone (low certainty).
1 finding from 1 review
Intervention not reported
Failure of re‐epithelialisation by day 21 post‐injury Image analysis of digital photographs · people with moderate acute ocular burns
It is very uncertain whether the intervention changes failure of re‐epithelialisation by day 21 post‐injury Image analysis… (very low certainty).
1 finding from 1 review
Intervention not reported
**Visual acuity at final · people with moderate acute ocular burns
1 finding from 1 review
Intervention not reported
Corneal neovascularisation Number of quadrants affected · people with moderate acute ocular burns
It is very uncertain whether the intervention changes corneal neovascularisation Number of quadrants affected (very low certainty).
1 finding from 1 review
Intervention not reported
Symblepharon Presence of symblepharon · people with moderate acute ocular burns
It is very uncertain whether the intervention changes symblepharon Presence of symblepharon (very low certainty).
1 finding from 1 review
Intervention not reported
Time‐to‐epithelialisation (days) · people with moderate acute ocular burns
1 finding from 1 review
Intervention not reported
Adverse effects · people with moderate acute ocular burns
1 finding from 1 review